Destiny Pharma welcomes the G20 Leaders´ Declaration on Combatting Antimicrobial Resistance (AMR) following their meeting in Germany. The G20 Leaders highlighted:
- The importance of fostering Research & Development, particularly for priority pathogens as identified by the WHO
- Called for the establishment of a new international Research & Development Collaboration Hub to maximise the impact of existing and new anti-microbial basic and clinical research initiatives, as well as product development
- Invited all interested countries and partners to join this new initiative
- The G20 Leaders will also, in collaboration with relevant experts including from the OECD and the WHO, further examine practical market incentive options
The full G20 Leaders’ Declaration can be found here.